Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06564987 · ClinicalTrials.gov registry record · Phase 1
Risk of Nerve Damage After Administration of Local Anesthesia
A Phase 1 study of Inferior Alveolar Nerve Injuries, sponsored by Cleveland Dental Institute.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 80
- Enrollment target
- 2
- Study locations
NCT06564987: Recruiting Phase 1 study of Inferior Alveolar Nerve Injuries, sponsored by Cleveland Dental Institute.
NCT06564987 is a Phase 1 study of Inferior Alveolar Nerve Injuries that is actively recruiting participants, run by Cleveland Dental Institute. The registered enrollment target is 80 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% higher). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06564987, a Phase 1 study of Inferior Alveolar Nerve Injuries, is actively recruiting participants, sponsored by Cleveland Dental Institute.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 80 participants
- Enrollment target
- 2
- Study locations
Study Summary
This research aims to evaluate of the risk of nerve damage following the administration of articaine 4% and lidocaine 2% for Inferior Alveolar nerve Block (IANB). A Randomized Controlled Clinical Trial will be conducted where the patient will be randomly assigned to one the two groups; articaine 4% and Lidocaine 2%. The type of LA will be concealed to the operator, investigators and assessors. The patients will be monitored for any aigns of nerve parathesia for 3 months after the procedure.
Conditions Studied
Interventions
- DRUG 4% Articaine with 1:200,000 epinephrine
- DRUG 2% lidocaine with 1:100,000 epinephrine
Study Locations (2)
Ohio
- Cleveland Dental Institute - Akron
- Cleveland Dental Institute - Ashtabula
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2024-01-01 |
| Est. Completion | 2025-03-31 |
| Phase | Phase 1 |
What NCT06564987 shows while recruiting
NCT06564987 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% higher).
The record links to 1 condition, with Inferior Alveolar Nerve Injuries appearing as the primary indexed condition, and to 2 interventions - of which 4% Articaine with 1:200,000 epinephrine is the first listed.
NCT06564987 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT06564987 about?
NCT06564987 is a clinical study titled "Risk of Nerve Damage After Administration of Local Anesthesia". This research aims to evaluate of the risk of nerve damage following the administration of articaine 4% and lidocaine 2% for Inferior Alveolar nerve Block (IANB). A Randomized Controlled Clinical Trial will be conducted where the patient will be randomly assigned to one the two groups; articaine 4% ...
What is the current status of trial NCT06564987?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2024-01-01. Estimated completion is 2025-03-31.
What conditions does trial NCT06564987 study?
This clinical trial studies the following conditions: Inferior Alveolar Nerve Injuries.
What interventions are being tested in trial NCT06564987?
The interventions under investigation include: 4% Articaine with 1:200,000 epinephrine (DRUG), 2% lidocaine with 1:100,000 epinephrine (DRUG).
Who is sponsoring clinical trial NCT06564987?
This trial is sponsored by Cleveland Dental Institute, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06564987 being conducted?
This trial has 2 study locations across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06564987's enrollment target sits among peer trials
80 673rd of 2000 higher than 1,305 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI